Department of Anesthesiology, Nanjing Drum Tower Hospital, Medical College of Nanjing University, Nanjing, People's Republic of China.
Department of Orthopaedic Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
J Bone Joint Surg Am. 2018 Apr 18;100(8):686-695. doi: 10.2106/JBJS.17.00375.
Current guidelines recommend restrictive criteria for red blood-cell transfusion in most clinical settings. However, patients undergoing orthopaedic surgery may require distinct transfusion criteria since benefits and potential harm often vary considerably based on patient characteristics and surgical procedures. We aimed to assess the efficacy and safety of restrictive transfusion in patients undergoing orthopaedic surgery, especially in important subgroups.
Electronic databases were searched to identify randomized controlled trials investigating restrictive (mostly a hemoglobin level of 8.0 g/dL or symptomatic anemia) versus liberal (mostly a hemoglobin level of 10.0 g/dL) transfusion in patients undergoing orthopaedic surgery. For the primary outcome of cardiovascular events, we performed random-effects meta-analyses to synthesize the evidence and to assess the effects in different subgroups according to patient characteristics (with versus without preexisting cardiovascular disease) and surgical procedures (hip fracture surgery versus elective arthroplasty).
Ten trials involving 3,968 participants who underwent hip or knee surgery were included. Mean participant age ranged from 68.7 to 86.9 years. Compared with liberal transfusion, restrictive transfusion increased the risk of cardiovascular events (8 trials; 3,618 participants; relative risk [RR], 1.51; 95% confidence interval [CI], 1.16 to 1.98; p = 0.003; with no heterogeneity across all trials), irrespective of preexisting cardiovascular disease (pinteraction = 0.63). In a subgroup analysis, the increase was observed in patients undergoing hip fracture surgery (RR, 1.51; 95% CI, 1.08 to 2.10; p = 0.02), but did not reach significance in those undergoing elective arthroplasty (RR, 1.53; 95% CI, 0.96 to 2.44; p = 0.07). To minimize the bias caused by variations in transfusion threshold, we conducted an analysis that only included trials using 8.0 g/dL hemoglobin or symptomatic anemia as the threshold for restrictive transfusion and obtained identical results (6 trials; 2,872 participants; RR, 1.51; 95% CI, 1.09 to 2.08; p = 0.01; I = 0%). The 2 arms did not differ with respect to the rates of all infections, 30-day mortality, thromboembolic events, wound infection, pulmonary infection (mainly pneumonia), and cerebrovascular accidents (mainly stroke).
In patients undergoing orthopaedic surgery, when compared with liberal transfusion, restrictive transfusion increases the risk of cardiovascular events irrespective of preexisting cardiovascular disease. Importantly, the increased risk was observed in patients undergoing hip fracture surgery but did not reach significance in those undergoing elective arthroplasty.
Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
目前的指南建议在大多数临床情况下对红细胞输血采用限制标准。然而,接受矫形外科手术的患者可能需要不同的输血标准,因为受益和潜在危害通常根据患者特征和手术程序而有很大差异。我们旨在评估限制输血在接受矫形外科手术的患者中的疗效和安全性,尤其是在重要的亚组中。
电子数据库被搜索以确定随机对照试验,这些试验调查了限制输血(大多为血红蛋白水平 8.0 g/dL 或有症状性贫血)与自由输血(大多为血红蛋白水平 10.0 g/dL)在接受矫形外科手术的患者中的应用。对于心血管事件的主要结局,我们进行了随机效应荟萃分析,以综合证据,并根据患者特征(是否存在预先存在的心血管疾病)和手术程序(髋部骨折手术与择期关节置换术)评估不同亚组中的效果。
纳入了 10 项涉及 3968 名接受髋部或膝关节手术的患者的试验。参与者的平均年龄范围为 68.7 岁至 86.9 岁。与自由输血相比,限制输血增加了心血管事件的风险(8 项试验;3618 名参与者;相对风险 [RR],1.51;95%置信区间 [CI],1.16 至 1.98;p = 0.003;所有试验之间无异质性),无论是否存在预先存在的心血管疾病(p 交互 = 0.63)。在亚组分析中,这种增加在接受髋部骨折手术的患者中观察到(RR,1.51;95%CI,1.08 至 2.10;p = 0.02),但在接受择期关节置换术的患者中未达到显著水平(RR,1.53;95%CI,0.96 至 2.44;p = 0.07)。为了最大程度地减少由于输血阈值的变化引起的偏倚,我们进行了一项仅包括使用 8.0 g/dL 血红蛋白或有症状性贫血作为限制输血阈值的试验的分析,并得到了相同的结果(6 项试验;2872 名参与者;RR,1.51;95%CI,1.09 至 2.08;p = 0.01;I = 0%)。两组在所有感染、30 天死亡率、血栓栓塞事件、伤口感染、肺部感染(主要是肺炎)和脑血管意外(主要是中风)的发生率方面没有差异。
在接受矫形外科手术的患者中,与自由输血相比,限制输血增加了心血管事件的风险,无论是否存在预先存在的心血管疾病。重要的是,这种风险增加在接受髋部骨折手术的患者中观察到,但在接受择期关节置换术的患者中未达到显著水平。
治疗性 1 级。请参阅作者说明,以获取完整的证据水平描述。